Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1-REM; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab182918-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $79.90 | |
| Ab182918-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $369.90 | |
| Ab182918-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $949.90 | |
| Ab182918-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,519.90 |
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1-REM; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Botensilimab (anti-CTLA4) - Primary antibody, specific to CTLA4, Human IgG1 |
|---|---|
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CTLA4 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description | Botensilimab (anti-CTLA4), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab (anti-CTLA4) can be used for the research of cancer. |
| Isotype | Human IgG1-REM |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 144.54 kDa |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 2408310-37-0 |
Botensilimab (anti-CTLA-4) (Ab182918) - ELISA
Immobilized Recombinant Human CTLA-4 protein (rp176276) at 1.0 μg/mL can bind Botensilimab (anti-CTLA-4) (Ab182918) with the EC
₅₀
of 29.07 ng/mL.
Botensilimab (anti-CTLA-4) (Ab182918) - SEC
The purity of Botensilimab (anti-CTLA-4) (Ab182918) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
